Ostatní
Návod 
Arrowhead Pharmaceuticals, Inc.
ARWR
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
5.6B
Obrat
1B
Zisk
0B
Aktiva
1B
Dluh
1B
ROE
0%
ROA
0%
PE
39
PS
7
Cena 1R
10-77
⌀ Cena
30.73
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
09-02-2026
Poslední dividenda
Profil
Arrowhead Pharmaceuticals, Inc. vyvíjí léčivé přípravky pro léčbu neléčitelných onemocnění ve Spojených státech. Produkty společnosti v potrubí zahrnují ARO-AAT, terapeutický kandidát na interferenci RNA (RNAi), který je ve fázi II klinické studie pro léčbu onemocnění jater spojených s nedostatkem antitrypsinu alfa- 1; ARO-APOC3, který je ve fázi 2b a v jedné fázi 3 klinické studie pro léčbu hypertriglyceridemie; ARO-ANG3, který je ve fázi 2b klinické studie pro snížení produkce proteinu podobného angiopoetinu 3; ARO-HSD, který je ve fázi 1/2a klinické studie pro léčbu onemocnění jater; ARO-ENaC , který je součástí klinické studie fáze 1/2a zaměřené na snížení produkce epiteliálního alfa kanálu sodného v dýchacích cestách plic; ARO-C3 pro léčbu onemocnění zprostředkovaného komplementem, které je předmětem klinické studie fáze 1/2a; ARO-Lung2 pro léčbu chronické obstrukční plicní poruchy; ARO-DUX4 pro léčbu facioskapulohumerální svalové dystrofie; ARO-XDH pro léčbu nekontrolované dny; ARO-COV pro léčbu COVID-19 a dalších plicních patogenů s; a ARO-HIF2, který je součástí klinické studie fáze 1b k léčbě karcinomu z čirých buněk ledvin. Podílí se také na vývoji JNJ-3989, subkutánně podávaného léčebného kandidáta RNAi k léčbě chronické infekce virem hepatitidy B; Olpasiranu ke snížení tvorby apolipoproteinu A; a ARO-AMG1 k léčbě geneticky validovaných kardiovaskulárních cílů. Společnost Arrowhead Pharmaceuticals, Inc. má s Janssen Pharmaceuticals, Inc. dohodu o spolupráci v oblasti výzkumu a licence na vývoj léků ARO-JNJ1, ARO-JNJ2 a ARO-JNJ3 RNAi pro cílové hodnoty jaterní exprese a dohodu o spolupráci v oblasti licence a výzkumu s Takeda Pharmaceuticals U.S.A., Inc. na vývoji léčebných kandidátů RNAi pro léčbu jaterních onemocnění. Arrowhead Pharmaceuticals, Inc. byla založena v roce 1989 a sídlí v Pasadeně v Kalifornii.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
609
Založení
1993-12-16
Podobné společnosti
$ 42.05
+ $ 0.40
$ 54.30
- $ 0.82
$ 70.79
- $ 1.00
$ 87.47
+ $ 0.92
$ 199.73
+ $ 1.80
$ 30.13
- $ 2.12
$ 32.49
- $ 0.40
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 1,091.0 | 829.4 | 3.6 | 240.7 | 243.2 | 138.3 | 88.0 | 168.8 | 16.1 | 31.4 | 0.2 | 0.4 | 0.2 | 0.3 | 0.1 | 0.3 | 0.6 | |
| Cost of Revenues | 12.6 | 23.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Gross Profit | 1,084.8 | 805.5 | 3.6 | 240.7 | 243.2 | 138.3 | 88.0 | 168.8 | 16.1 | 31.4 | 0.2 | 0.4 | 0.2 | 0.3 | 0.1 | 0.3 | 0.6 |
| Revenue | 1-2026 | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 264.0 | 256.5 | 27.8 | 542.7 | 2.5 | 23.6 | 0.0 | 0.0 | 3.6 | 16.1 | |
| Cost of Revenues | 6.4 | 0.0 | 6.2 | 0.0 | 0.0 | 13.6 | 4.8 | 4.5 | 0.0 | 3.9 | |
| Gross Profit | 264.0 | 256.5 | 21.5 | 542.7 | 2.5 | 10.0 | -4.8 | -4.5 | 3.6 | 12.2 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 353.2 | 297.3 | 206.3 | 128.9 | 81.0 | 53.0 | 31.7 | 41.5 | 57.4 | 23.1 | 8.7 | 5.4 | 3.3 | 1.1 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 90.9 | 124.4 | 81.0 | 52.3 | 26.6 | 19.1 | 32.0 | 41.0 | 34.7 | 24.4 | 11.7 | 14.1 | 5.2 | 8.0 | |
| Depreciation & Amortization | 25.1 | 23.9 | 18.6 | 12.5 | 10.4 | 8.3 | 5.9 | 4.4 | 4.7 | 4.7 | 3.3 | 2.3 | 1.3 | 1.8 | 1.7 | 0.3 | 0.7 | |
| Total Operating Expenses | 784.2 | 707.2 | 604.6 | 445.7 | 421.7 | 287.3 | 181.2 | 107.6 | 72.1 | 68.4 | 79.9 | 96.4 | 51.3 | 23.6 | 21.2 | 10.1 | 9.4 | |
| Operating Income | 300.6 | 98.3 | -601.1 | -205.0 | -178.5 | -149.0 | -93.2 | 61.2 | -55.9 | -37.0 | -81.7 | -96.0 | -53.3 | -24.6 | -21.1 | -9.8 | -8.8 |
| Operating Income | TTM | 1-2026 | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 99.9 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 24.2 | ||
| Depreciation & Amortization | 6.4 | 6.4 | 6.2 | 6.1 | 5.2 | 5.0 | 4.8 | 4.5 | 4.3 | 3.9 | ||
| Total Operating Expenses | 223.2 | 212.4 | 187.1 | 161.5 | 163.9 | 162.2 | 176.1 | 126.2 | 140.1 | 124.4 | ||
| Operating Income | 40.8 | 44.1 | -165.6 | 381.2 | -161.4 | -162.2 | -176.1 | -126.2 | -136.5 | -108.3 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 39.4 | 37.3 | 22.7 | 15.3 | 5.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Interest Expense | 90.2 | 89.4 | 32.4 | 18.3 | 5.0 | 6.1 | 9,190.5 | 6,957.8 | 1,048.5 | 415.1 | 265.8 | 729.2 | 645.5 | 0.0 | 36.0 | 86.5 | -48.0 | |
| Other Expense | -42.2 | -46.8 | -11.4 | -1.5 | 5.8 | 8.2 | 8.6 | 7.0 | 0.4 | 2.2 | -2.3 | 3.3 | -8.3 | -8.3 | -1.1 | 1.0 | 1.5 | |
| IBT | 258.3 | 51.5 | -612.5 | -206.5 | -172.7 | -140.8 | -84.6 | 68.1 | -54.4 | -34.4 | -81.7 | -91.9 | -58.7 | -31.7 | -22.1 | -8.8 | 0.0 | |
| Income Tax Expense | 24.8 | 21.4 | -2.8 | 2.8 | 3.8 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | -22,110.6 | -8,785.0 | -3.2 | |
| Net Income | 202.3 | -1.6 | -599.5 | -205.3 | -176.5 | -140.8 | -84.6 | 68.0 | -54.5 | -34.4 | -81.7 | -91.9 | -58.6 | -31.1 | -21.1 | -3.1 | -5.8 |
| Net Income | TTM | 1-2026 | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 9.7 | 9.1 | 11.0 | 9.6 | 7.6 | 7.2 | 6.5 | 6.3 | 2.8 | 3.9 | ||
| Interest Expense | 22.5 | 21.7 | 24.4 | 21.6 | 21.6 | 14.6 | 5.1 | 7.2 | 5.4 | 5.3 | ||
| Other Expense | -12.5 | -8.0 | -10.1 | -11.6 | -13.7 | -10.6 | 2.2 | -0.8 | -2.1 | -0.7 | ||
| IBT | 28.3 | 36.1 | -175.7 | 369.6 | -175.1 | -172.8 | -174.0 | -127.0 | -138.7 | -109.0 | ||
| Income Tax Expense | 0.0 | 20.0 | 3.0 | 1.8 | 0.1 | 0.5 | 0.0 | 0.0 | -3.3 | 2.0 | ||
| Net Income | 30.8 | -23.8 | -175.2 | 370.4 | -173.1 | -170.5 | -170.8 | -125.3 | -132.9 | -109.7 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-1.91 | $-1.67 | $-1.36 | $-0.84 | $0.72 | $-0.65 | $-0.47 | $-1.34 | $-1.60 | $-1.25 | $-1.30 | $-1.90 | $-0.44 | $-0.90 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-1.92 | $-1.67 | $-1.36 | $-0.84 | $0.69 | $-0.65 | $-0.47 | $-1.34 | $-1.60 | $-1.25 | $-1.30 | $-1.90 | $-0.44 | $-0.90 | |
| Shares Outstanding | 140.1 | 133.8 | 119.8 | 107.3 | 105.4 | 103.7 | 100.7 | 93.9 | 83.6 | 73.9 | 61.1 | 57.4 | 46.9 | 24.0 | 11.1 | 7.2 | 6.4 | |
| Diluted Shares Outstanding | 140.7 | 133.8 | 119.8 | 106.8 | 105.4 | 103.7 | 100.7 | 98.6 | 83.6 | 73.9 | 61.1 | 57.4 | 46.9 | 24.0 | 11.1 | 7.2 | 6.4 |
| Per Share Data | TTM | 1-2026 | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-1.02 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-1.02 | ||
| Shares Outstanding | 140.1 | 135.7 | 139.0 | 133.4 | 124.8 | 122.0 | 124.2 | 123.3 | 107.4 | 107.3 | ||
| Diluted Shares Outstanding | 140.7 | 135.7 | 139.0 | 134.5 | 124.8 | 122.0 | 124.2 | 123.3 | 107.4 | 107.3 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 69.4 | 102.7 | 110.9 | 108.0 | 184.4 | 143.6 | 221.8 | 30.1 | 24.8 | 85.4 | 81.2 | 132.5 | 19.1 | 3.4 | 7.5 | 6.8 | |
| Short Term Investments | 367.3 | 578.3 | 292.7 | 268.4 | 183.4 | 171.9 | 36.9 | 46.4 | 40.8 | 0.0 | 17.5 | 21.7 | 9.0 | 0.1 | 0.6 | 0.0 | |
| Total Cash & ST Investments | 436.7 | 681.0 | 403.6 | 376.4 | 367.8 | 315.5 | 258.7 | 76.5 | 65.6 | 85.4 | 98.8 | 154.2 | 28.1 | 3.5 | 8.1 | 6.8 | |
| Accounts Receivable | 0.0 | 0.0 | 0.0 | 1.4 | 10.3 | 0.8 | 0.7 | 0.3 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 2.5 | 1.6 | 0.9 | |
| Inventory | 0.0 | 0.0 | 0.0 | -21.6 | 4.4 | 4.3 | 3.3 | 1.3 | 0.9 | 1.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | |
| Other Current Assets | 13.4 | 14.5 | 15.9 | 20.2 | 2.2 | 1.8 | 2.6 | 0.6 | 1.4 | 3.8 | 0.8 | 0.0 | 0.6 | 0.6 | 0.1 | 0.1 | |
| Total Current Assets | 450.1 | 695.5 | 419.5 | 376.4 | 384.6 | 322.4 | 265.2 | 78.8 | 67.9 | 90.5 | 102.9 | 154.8 | 28.8 | 6.6 | 9.9 | 8.1 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 129.8 | 185.7 | 53.9 | 102.7 | 69.4 | 127.7 | 58.2 | 110.9 | 105.3 | 135.0 | |
| Short Term Investments | 770.6 | 911.7 | 499.0 | 578.3 | 367.3 | 395.4 | 162.1 | 292.7 | 346.4 | 346.0 | |
| Total Cash & ST Investments | 900.4 | 1,097.4 | 552.9 | 681.0 | 436.7 | 523.1 | 220.3 | 403.6 | 451.7 | 481.0 | |
| Accounts Receivable | 9.7 | 2.4 | 2.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 | 69.4 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.1 | 9.9 | |
| Other Current Assets | 36.9 | 35.4 | 15.1 | 14.5 | 13.4 | 18.5 | 17.6 | 15.9 | 17.2 | 24.4 | |
| Total Current Assets | 946.9 | 1,135.2 | 570.5 | 695.5 | 450.1 | 541.7 | 237.9 | 419.5 | 470.2 | 574.8 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 420.3 | 431.3 | 335.6 | 168.6 | 66.0 | 47.0 | 23.2 | 13.9 | 15.5 | 15.4 | 4.5 | 3.9 | 3.5 | 4.9 | 0.0 | 0.1 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 9.0 | 8.6 | 10.3 | 12.0 | 13.7 | 15.4 | 17.1 | 18.8 | 20.5 | 22.2 | 24.8 | 1.0 | 3.2 | 4.8 | 1.7 | 2.0 | |
| Long-Term Investments | 0.0 | 0.0 | 0.0 | 105.9 | 245.6 | 137.5 | 44.2 | 0.0 | 0.0 | 0.0 | 0.0 | 23.1 | 0.0 | 0.0 | 1.8 | 2.0 | |
| Other Long-Term Assets | 4.5 | 4.5 | 0.2 | 29.1 | 0.3 | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 1.7 | 0.3 | 2.4 | 0.0 | |
| Total Long-Term Assets | 433.7 | 444.3 | 346.0 | 315.5 | 325.6 | 200.1 | 84.6 | 32.8 | 36.1 | 37.7 | 29.4 | 28.0 | 8.5 | 10.0 | 6.0 | 4.2 | |
| Total Assets | 883.8 | 1,139.8 | 765.6 | 691.9 | 710.1 | 522.5 | 349.8 | 111.6 | 104.0 | 128.2 | 132.3 | 182.8 | 37.3 | 16.5 | 15.9 | 12.4 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 425.1 | 429.3 | 431.9 | 431.3 | 420.3 | 403.9 | 378.3 | 335.6 | 272.0 | 226.3 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 7.3 | 7.7 | 8.1 | 8.6 | 9.0 | 9.4 | 9.8 | 10.3 | 10.7 | 11.1 | |
| Long-Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 42.8 | 78.8 | |
| Other Long-Term Assets | 1.4 | 1.3 | 3.1 | 4.5 | 4.5 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |
| Total Long-Term Assets | 433.7 | 438.3 | 443.2 | 444.3 | 433.7 | 413.5 | 388.4 | 346.0 | 325.7 | 316.5 | |
| Total Assets | 1,380.6 | 1,573.5 | 1,013.7 | 1,139.8 | 883.8 | 955.2 | 626.3 | 765.6 | 795.9 | 891.3 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 26.6 | 11.4 | 35.9 | 2.9 | 9.5 | 6.8 | 7.6 | 2.8 | 4.1 | 12.2 | 5.0 | 2.6 | 1.2 | 0.9 | 0.6 | 0.7 | |
| Short-Term Debt | 6.1 | 6.3 | 9.7 | 2.8 | 2.3 | 1.1 | 11.6 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 1.2 | 0.2 | 0.0 | 0.5 | |
| Other Current Liabilities | 64.1 | 85.4 | 58.2 | -5.6 | 23.8 | 13.5 | 0.0 | 9.3 | 9.1 | 10.6 | 10.5 | 8.9 | 6.2 | 4.2 | 2.0 | 2.4 | |
| Current Liabilities | 96.7 | 103.2 | 105.5 | 74.1 | 146.5 | 40.7 | 97.1 | 12.4 | 18.7 | 25.6 | 15.9 | 11.8 | 8.7 | 5.3 | 2.6 | 4.3 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 33.1 | 10.0 | 14.5 | 11.4 | 26.6 | 8.5 | 4.5 | 35.9 | 7.9 | 9.6 | |
| Short-Term Debt | 47.0 | 71.8 | 8.2 | 6.3 | 6.1 | 10.6 | 6.8 | 21.1 | 5.6 | 5.4 | |
| Other Current Liabilities | 91.5 | 95.5 | 71.1 | 85.4 | 64.1 | 46.1 | 52.4 | 47.6 | 39.8 | 79.2 | |
| Current Liabilities | 194.5 | 220.5 | 93.8 | 103.2 | 96.7 | 65.2 | 63.7 | 105.5 | 70.2 | 87.2 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 336.0 | 504.2 | 372.9 | 78.8 | 23.3 | 20.0 | 0.0 | 2.1 | 2.3 | 2.5 | 0.5 | 0.8 | 1.1 | 2.1 | 0.6 | 0.0 | |
| Capital Leases | 112.0 | 117.4 | 115.2 | 81.6 | 25.5 | 21.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 1.0 | 1.3 | 1.5 | 0.0 | 0.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 544.8 | 948.7 | 478.4 | 586.0 | 301.3 | 60.7 | 105.8 | 16.4 | 23.2 | 33.2 | 22.6 | 16.8 | 11.6 | 7.7 | 3.3 | 4.3 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 666.3 | 668.7 | 517.1 | 504.2 | 448.1 | 113.6 | 388.8 | 104.6 | 79.9 | 80.1 | |
| Capital Leases | 112.7 | 114.3 | 115.9 | 117.4 | 118.1 | 113.6 | 118.6 | 115.2 | 82.7 | 82.8 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 860.8 | 889.3 | 957.6 | 948.7 | 544.8 | 459.7 | 452.6 | 478.4 | 413.9 | 426.2 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.2 | 0.2 | 0.2 | 106.0 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Retained Earnings | -1,455.0 | -1,625.5 | -1,026.0 | -820.8 | -644.7 | -503.8 | -419.3 | -487.3 | -432.8 | -398.4 | -316.7 | -224.8 | -166.1 | -135.0 | -113.9 | -110.7 | |
| Comprehensive Income | -1.0 | 4.8 | -3.2 | -0.1 | -0.1 | 0.0 | -0.4 | 0.0 | 0.0 | 0.0 | -0.1 | -4.2 | -3.1 | -1.6 | -0.3 | -1.2 | |
| Total Common Equity | 330.5 | 185.4 | 271.3 | 106.0 | 408.8 | 461.8 | 244.6 | 95.8 | 81.4 | 95.6 | 110.2 | 166.5 | 27.5 | 10.0 | 12.8 | 9.0 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |
| Retained Earnings | -1,603.4 | -1,428.2 | -1,798.6 | -1,625.5 | -1,455.0 | -1,284.2 | -1,158.9 | -1,026.0 | -916.4 | -813.4 | |
| Comprehensive Income | 5.4 | 4.4 | 4.1 | 4.8 | -1.0 | -1.1 | -1.3 | -3.2 | -0.4 | -0.3 | |
| Total Common Equity | 519.8 | 683.3 | 52.6 | 185.4 | 330.5 | 483.8 | 160.4 | 271.3 | 364.8 | 446.8 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 454.1 | 510.6 | 115.2 | 81.6 | 25.5 | 21.1 | 0.0 | 2.3 | 2.5 | 2.7 | 0.8 | 1.0 | 2.3 | 2.3 | 0.6 | 0.5 | |
| Book Value | 339.0 | 191.1 | 287.2 | 106.0 | 408.8 | 461.8 | 244.0 | 95.2 | 80.9 | 95.0 | 109.6 | 166.0 | 25.7 | 8.8 | 12.6 | 8.1 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | -2.5 | 0.9 | 3.5 | 5.6 | 8.4 | 11.6 | 13.3 | 15.8 | 17.2 | 18.3 | |
| Book Value | 519.8 | 683.3 | 52.6 | 185.4 | 330.5 | 483.8 | 160.4 | 271.3 | 364.8 | 446.8 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -542.5 | 30.1 | -609.7 | -209.3 | -176.5 | -140.8 | -84.6 | 68.0 | -54.5 | -34.4 | -81.7 | -91.9 | -58.6 | -31.1 | 0.0 | -8.8 | -6.2 | |
| Depreciation & Amortization | 17.4 | 23.9 | 18.6 | 12.5 | 10.4 | 8.3 | 5.9 | 4.4 | 4.7 | 4.7 | 3.3 | 2.3 | 1.3 | 1.8 | 1.7 | 0.3 | 0.7 | |
| Stock-Based Compensation | 72.7 | 63.4 | 74.0 | 78.1 | 120.9 | 76.7 | 43.4 | 12.4 | 8.5 | 7.9 | 11.6 | 10.2 | 5.7 | 1.5 | 1.2 | 1.4 | 1.6 | |
| Change Working Capital | 76.6 | -18.2 | 25.1 | -51.5 | -98.3 | 226.9 | -60.7 | 87.2 | -5.9 | -1.2 | 5.7 | 3.4 | 5.0 | 0.1 | 0.2 | 0.0 | -1.0 | |
| Change In Accounts Receivable | 1.2 | -57.0 | 0.0 | 1.4 | 8.8 | -9.4 | -0.2 | -0.3 | -0.3 | 0.0 | -0.1 | 0.0 | 0.1 | -0.1 | 162.9 | 0.0 | 0.0 | |
| Change In Accounts Payable | 30.8 | 6.3 | -5.5 | 33.0 | -6.6 | 2.6 | -0.8 | 4.8 | -1.3 | -3.5 | 2.6 | 2.5 | 1.4 | 0.3 | 0.3 | 0.2 | -0.3 | |
| Change In Inventories | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 9.2 | 1.6 | -1.3 | 1.3 | 2.4 | -1.9 | 0.0 | -139.4 | -20.2 | -162.9 | 0.0 | 0.0 | |
| Other Non-cash Items | 66.0 | 80.4 | 29.2 | 16.3 | 7.3 | 0.3 | 0.5 | 1.1 | 0.4 | 0.0 | -5.6 | 13.1 | 3.1 | 1.0 | -18.0 | 0.2 | -2.7 | |
| Cash from Operations | -350.9 | 0.0 | 0.0 | -153.9 | -136.1 | 171.2 | -95.4 | 173.0 | -47.2 | -23.9 | -64.4 | -65.7 | -35.4 | -19.0 | -15.3 | -5.4 | -7.7 |
| Cash Flow From Operating Activities | 1-2026 | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 28.2 | 16.1 | -178.7 | 367.9 | -175.2 | -173.3 | -174.0 | -127.0 | -132.9 | -111.0 | |
| Depreciation & Amortization | 6.4 | 6.4 | 6.2 | 6.1 | 5.2 | 5.0 | 4.8 | 4.5 | 4.3 | 3.9 | |
| Stock-Based Compensation | 19.4 | 19.1 | 13.0 | 16.0 | 15.2 | 19.5 | 17.1 | 17.8 | 19.7 | 18.2 | |
| Change Working Capital | -61.8 | -38.4 | -18.0 | 45.5 | -7.4 | 8.0 | 24.6 | 3.4 | -10.9 | 59.4 | |
| Change In Accounts Receivable | -212.0 | -47.1 | -7.5 | 0.1 | -2.5 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 | |
| Change In Accounts Payable | 15.3 | -15.4 | 23.4 | -4.8 | 3.1 | -8.3 | 11.2 | 4.1 | -12.5 | 28.0 | |
| Change In Inventories | -0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | |
| Other Non-cash Items | 21.3 | 17.3 | 22.6 | 24.6 | 15.9 | 3.7 | 12.1 | 9.0 | 1.9 | 6.3 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -25.3 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -181.1 | -22.7 | -141.5 | -176.7 | -52.8 | -23.6 | -12.0 | -12.0 | -1.4 | -7.9 | -3.9 | -2.0 | -1.7 | -0.3 | -0.5 | 0.0 | 0.0 | |
| Acquisitions | -94.4 | 0.0 | 0.0 | -80.6 | 0.0 | 141.7 | 240,777.8 | 47,746.0 | 7,435.0 | 0.0 | 0.0 | -10.0 | 0.0 | 0.0 | 0.1 | -1.7 | 0.0 | |
| Investments | -440.8 | -796.3 | -720.9 | -246.1 | -223.4 | -240.7 | -279.0 | -90.3 | -52.1 | -45.0 | 0.0 | 0.0 | -46.4 | -10.7 | 0.0 | 1,700.4 | 0.0 | |
| Sales of Investment | 455.2 | 689.6 | 442.3 | 326.7 | 270.8 | 122.6 | 50.1 | 54.5 | 46.1 | 4.2 | 17.3 | 26.1 | 11.6 | 1.4 | 0.5 | 1.5 | 0.0 | |
| Other Investing Activities | -7.0 | 0.0 | 0.0 | 80.6 | 0.0 | -141.7 | -240,777.8 | -47,746.0 | -7,435.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.3 | -1,700.4 | 0.5 | |
| Cash from Investing | -166.6 | 0.0 | 0.0 | -96.2 | -5.4 | -141.7 | -240.8 | -47.7 | -7.4 | -48.6 | 13.4 | 14.1 | -36.5 | -9.5 | 0.4 | -0.2 | 0.5 |
| Cash Flow From Investing Activities | 1-2026 | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -2.1 | -7.5 | -2.4 | -5.3 | -7.5 | -24.3 | -14.4 | -34.1 | -68.7 | -63.9 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -94.4 | |
| Investments | -136.9 | -21.6 | -96.7 | -644.1 | -33.7 | -292.3 | -118.6 | -310.0 | 0.0 | -12.2 | |
| Sales of Investment | 115.3 | 101.8 | 240.5 | 229.2 | 118.2 | 93.7 | 140.0 | 75.1 | 133.5 | 106.6 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 94.4 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 30.5 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -300.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.4 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | 0.0 | -0.7 | |
| Debt Issued | 671.4 | 510.6 | 395.4 | 33.6 | 56.0 | 4.4 | 21.1 | 0.1 | 0.0 | 0.0 | 2.2 | -0.1 | -1.1 | 0.2 | 1.9 | 0.1 | 1.2 | |
| Issuance of Common Stock | 432.3 | 0.0 | 0.0 | 3.1 | 5.2 | 0.0 | 250.5 | 60.5 | 56.6 | 12.4 | 52.2 | 0.0 | 172.6 | 44.5 | 11.0 | 6.2 | 12.2 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 431.2 | 0.0 | 0.0 | 253.1 | 60.0 | 11.3 | 7.5 | 8.3 | 3.6 | -0.2 | 3.1 | 0.5 | 12.9 | 0.0 | 0.0 | 0.0 | 0.6 | |
| Cash from Financing | 481.6 | 0.0 | 0.0 | 253.1 | 65.2 | 11.3 | 257.9 | 66.4 | 60.0 | 12.1 | 55.1 | 0.3 | 185.3 | 44.3 | 10.8 | 6.2 | 12.0 |
| Cash Flow From Financing Activities | 1-2026 | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 0.0 | 713.3 | -27.2 | 215.2 | 14.7 | 56.4 | 54.3 | 7.6 | 277.1 | 32.4 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -35.9 | 123.9 | -8.2 | 2.9 | -76.4 | 40.9 | -78.2 | 191.7 | 5.3 | -60.5 | 4.2 | -51.3 | 113.4 | 15.7 | -4.1 | 0.7 | 4.8 | |
| Closing Cash Balance | 69.4 | 226.5 | 102.7 | 110.9 | 108.0 | 184.4 | 143.6 | 221.8 | 30.1 | 24.8 | 85.4 | 81.2 | 132.5 | 19.1 | 3.4 | 7.5 | 6.8 |
| Cash position | 1-2026 | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -24.9 | 96.8 | -55.9 | 131.8 | -48.8 | 33.3 | -58.3 | 69.5 | -52.7 | 5.6 | |
| Closing Cash Balance | 201.6 | 226.5 | 129.8 | 185.7 | 53.9 | 102.7 | 69.4 | 127.7 | 58.2 | 110.9 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -532.0 | 156.9 | -604.3 | -330.6 | -188.9 | 147.7 | -107.3 | 161.0 | -48.6 | -31.9 | -68.3 | -67.7 | -37.1 | -19.3 | -15.8 | -5.4 | -7.7 | |
| Real Free Cash Flow | -604.7 | 93.5 | -678.3 | -408.8 | -309.8 | 71.0 | -150.7 | 148.6 | -57.1 | -39.7 | -79.9 | -77.9 | -42.8 | -20.9 | -17.1 | -6.8 | -9.3 |
| Free Cash Flow | 1-2026 | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 11.3 | 13.0 | -157.1 | 454.8 | -153.8 | -161.5 | -129.9 | -126.5 | -186.5 | -89.2 | |
| Real Free Cash Flow | -8.0 | -6.1 | -170.1 | 438.7 | -169.0 | -181.0 | -146.9 | -144.2 | -206.2 | -107.3 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 39.2 | -7.3 | -1.4 |
| P/S | 7.3 | 466.9 | 9.4 |
| P/B | 15.2 | 8.5 | 5.2 |
| P/FCF | 31.1 | -4.4 | -1.5 |
| Market cap | $5.6 | $3.1 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 0 % | 8.6 % | 0 % |
| Debt to Income | 352.6 % | -29.4 % | 0 % |
| Debt to Free cash flow | 280.3 % | -1796.7 % | 0 % |
| Interest expense percentage | 30 % | 14435.5 % | 44.7 % |
| Current ratio | 4.9 | 5.1 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 38.9 % | -86 % | 0 % |
| ROA | 14.7 % | -39.4 % | 0 % |
| CapEx to Revenue | 1.6 % | 327.2 % | 0 % |
| RaD to Revenue | 0 % | 3691 % | 0 % |
| ROEM | 1,534,431.8 | 523414.3 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 99.4 % | -668.4 % | 68.7 % |
| Operating margin | 27.6 % | -7098.3 % | 35.5 % |
| Net margin | 18.5 % | -7386.2 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | 0 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 140.7 mil | 70.7 mil |
| Employee count | 0.7 tis | 0.2 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
